| Title |
Available and emerging treatments for Parkinson’s disease: a review
|
|---|---|
| Published in |
Drug Design, Development and Therapy, May 2011
|
| DOI | 10.2147/dddt.s11836 |
| Pubmed ID | |
| Authors |
Mark Stacy, Patrick Hickey, Mark Stacy |
| Abstract |
Parkinson's disease is a commonly encountered neurodegenerative disorder primarily found in aged populations. A number of medications are available to control symptoms, although these are less effective in advanced disease. Deep brain stimulation provides a practicable alternative at this stage, although a minority of patients meet the strict criteria for surgery. Novel medications that provide enhanced symptomatic control remain in developmental demand. Both gene and cell-based therapies have shown promise in early clinical studies. A major unmet need is a treatment that slows or stops disease progression. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Canada | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 193 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Germany | 3 | 2% |
| Australia | 1 | <1% |
| India | 1 | <1% |
| United Kingdom | 1 | <1% |
| United States | 1 | <1% |
| Unknown | 186 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 50 | 26% |
| Student > Master | 25 | 13% |
| Student > Ph. D. Student | 23 | 12% |
| Researcher | 18 | 9% |
| Student > Doctoral Student | 9 | 5% |
| Other | 32 | 17% |
| Unknown | 36 | 19% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 41 | 21% |
| Agricultural and Biological Sciences | 31 | 16% |
| Neuroscience | 23 | 12% |
| Psychology | 13 | 7% |
| Biochemistry, Genetics and Molecular Biology | 12 | 6% |
| Other | 26 | 13% |
| Unknown | 47 | 24% |
Attention Score in Context
This research output has an Altmetric Attention Score of 628. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 April 2024.
All research outputs
#35,944
of 25,728,855 outputs
Outputs from Drug Design, Development and Therapy
#2
of 2,280 outputs
Outputs of similar age
#66
of 122,432 outputs
Outputs of similar age from Drug Design, Development and Therapy
#1
of 7 outputs
Altmetric has tracked 25,728,855 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,280 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.6. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 122,432 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 7 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them